Advertisement

Topics

Pfizer’s lung cancer drug lorlatinib succeeds in phase 2 trial

05:44 EDT 17 Oct 2017 | Pharmaceutical Business Review

Pfizer says that its investigational, next-generation tyrosine kinase inhibitor lorlatinib showed clinically meaningful activity against lung tumors and brain metastases in a phase 2 trial in patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer (NSCLC).

Original Article: Pfizer’s lung cancer drug lorlatinib succeeds in phase 2 trial

NEXT ARTICLE

More From BioPortfolio on "Pfizer’s lung cancer drug lorlatinib succeeds in phase 2 trial"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...